OXUR Stock Overview
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Oxurion NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0001 |
| 52 Week High | €0.008 |
| 52 Week Low | €0.0001 |
| Beta | 0.51 |
| 1 Month Change | 0% |
| 3 Month Change | -80.00% |
| 1 Year Change | -97.87% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
What Type Of Returns Would Oxurion's(EBR:OXUR) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Feb 01
How Is Oxurion's (EBR:OXUR) CEO Compensated?
Dec 09
Here's What We Learned About The CEO Pay At Oxurion NV (EBR:OXUR)
Aug 20Oxurion (EBR:OXUR) Share Prices Have Dropped 43% In The Last Year
Jul 17Shareholder Returns
| OXUR | BE Biotechs | BE Market | |
|---|---|---|---|
| 7D | 0% | 0.2% | 2.4% |
| 1Y | -97.9% | -11.3% | -2.8% |
Return vs Industry: OXUR underperformed the Belgian Biotechs industry which returned -12.9% over the past year.
Return vs Market: OXUR underperformed the Belgian Market which returned -3.3% over the past year.
Price Volatility
| OXUR volatility | |
|---|---|
| OXUR Average Weekly Movement | 80.4% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in BE Market | 7.7% |
| 10% least volatile stocks in BE Market | 2.5% |
Stable Share Price: OXUR's share price has been volatile over the past 3 months.
Volatility Over Time: OXUR's weekly volatility has increased from 46% to 80% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 20 | Pascal Ghoson | www.oxurion.com |
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist, which is in Phase II clinical trials for the treatment of DME.
Oxurion NV Fundamentals Summary
| OXUR fundamental statistics | |
|---|---|
| Market cap | €575.40k |
| Earnings (TTM) | -€18.97m |
| Revenue (TTM) | €263.00k |
2.2x
P/S Ratio0.0x
P/E RatioIs OXUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OXUR income statement (TTM) | |
|---|---|
| Revenue | €263.00k |
| Cost of Revenue | €159.00k |
| Gross Profit | €104.00k |
| Other Expenses | €19.07m |
| Earnings | -€18.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0033 |
| Gross Margin | 39.54% |
| Net Profit Margin | -7,212.55% |
| Debt/Equity Ratio | -91.1% |
How did OXUR perform over the long term?
See historical performance and comparison